BIIB – biogen inc. (US:NASDAQ)

DELAYED

^$ usd


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

1D

5D

1M

3M

YTD

1Y

3Y

1 Day BIIB SPY QQQ SPX

Date

Time

Symbol

Headline

Impact

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi [Yahoo! Finance]

European regulators OK Alzheimer's treatment Leqembi after initial doubts [Yahoo! Finance Canada]

Biogen Inc. (NASDAQ: BIIB) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.

Leqembi®? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union [Yahoo! Finance]

Leqembi®? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Morgan Stanley from $157.00 to $152.00. They now have an "equal weight" rating on the stock.

Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Date

Time

Symbol

Company Name

Action

%Chg

Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.

Date

Time

Action

From

To

Firm

Impact

%Chg

details

Needham & Company LLC

Date

Time

Symbol

Headline

Impact

Form SCHEDULE 13G/A BIOGEN INC. Filed by: BlackRock, Inc.

Form 4 BIOGEN INC. For: Apr 01 Filed by: Godbout Sean

Form 4 BIOGEN INC. For: Mar 07 Filed by: SHERWIN STEPHEN A

Form 3 BIOGEN INC. For: Mar 01 Filed by: Godbout Sean

Form 144 BIOGEN INC. Filed by: SHERWIN STEPHEN A

Form 4 BIOGEN INC. For: Feb 10 Filed by: Singhal Priya

Form 4 BIOGEN INC. For: Feb 10 Filed by: Murphy Nicole

Form 4 BIOGEN INC. For: Feb 10 Filed by: MCDONNELL MICHAEL R

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size

Shares at ask / bid

Off exchange

Top News Gainers

10/22 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies 25.3%

2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%

3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%

3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%

3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%

7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%

4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%

3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%

2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%

11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%

Top News Decliners

10/22 Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch] -11.9%

2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%

3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%

4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%

2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%

3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%

1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%

10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%

1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%

10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: